Diabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh

Similar documents
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

New Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum

Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse

sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd

National Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes

DR HJ BODANSKY MD FRCP CONSULTANT PHYSICIAN LEEDS TEACHING HOSPITALS ASSOCIATE PROFESSOR, UNIVERSITY OF LEEDS

Diabetes Mellitus case studies. Jana Vinklerová

Barns Medical Practice Service Specification: Diabetes

UK launch of once-daily tablet from Janssen provides new option to improve blood glucose control for thousands of people with Type 2 diabetes 1

Dept of Diabetes Main Desk

YOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013

How can we improve outcomes in Type 2 diabetes?

Hanyang University Guri Hospital Chang Beom Lee

Management of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control

667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY

There have been important changes in diabetes care which may not be covered in undergraduate textbooks.

Diabetes - The Facts

IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS

Diabetes Mellitus Aeromedical Considerations. Aviation Medicine Seminar Bucharest, Romania. 11 th to 15 th November 2013

Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol

GLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks

Chief of Endocrinology East Orange General Hospital

Type 2 diabetes in adults: controlling your blood glucose by taking a second medicine what are your options?

Why do we care? 20.8 million people. 70% of people with diabetes will die of cardiovascular disease. What is Diabetes?

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

Medical therapy advances London/Manchester RCP February/June 2016

Diabetes and stroke. What is the link between diabetes and stroke? What is diabetes? What are the symptoms of diabetes?

Glucose Control drug treatments

Diabetes in the UK: Update on Diabetes Treatment and Care. Why is diabetes increasing? Obesity Increased waist circumference.

Common Diabetes-related Terms

Management of Type 2 Diabetes

Diabetes. Ref HSCW 024

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Type 2 diabetes: the management of type 2 diabetes (update)

Wayne Gravois, MD August 6, 2017

Summary of the risk management plan (RMP) for Synjardy (empagliflozin / metformin)

Dr Tahseen A. Chowdhury Royal London Hospital. New Guidelines in Diabetes: NICE or Nasty?

Drug Class Review Newer Diabetes Medications and Combinations

GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

PERIOPERATIVE DIABETES GUIDELINE

Diabetes Education Columbus Community Hospital Stacy Biesel RN, CDE

Oral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care

Diabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker

Diabetes Prevention & Management of Complications

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Diabetes(Mellitus( Dr(Kawa(A.(Obeid( PhD!Therapeutics!

National Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008

Diabetes Management: A diagnostic perspective

Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville

Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP

Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study

Chapter 24 Diabetes Mellitus

Objectives. How Medicine Works to Control Blood Sugar Levels. What Happens When We Eat? What is diabetes? High Blood Glucose (Hyperglycemia)

Diabetes and Kidney Disease: Time to Act. Your Guide to Diabetes and Kidney Disease

TUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees Diabetes Mellitus DIABETES MELLITUS

Dr A Pokrajac MD MSc MRCP Consultant

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol

The Endocrine Pancreas (Chapter 10) *

empagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly

What s New on the Horizon: Diabetes Medication Update

SGLT2 Inhibitors

SGLT2 Inhibitors

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

WHO Guidelines for Management of Diabetes in Low Resource Settings

A Guidance Statement from the American College of Physicians

Drugs used in Diabetes. Dr Andrew Smith

Diabetes Mellitus I INTRODUCTION

01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Mr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)

Diabetes 101: A Brief Overview of Diabetes and the American Diabetes Association

Training Your Caregiver: Diabetes

Bristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium

Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus

Scottish Medicines Consortium

Objectives 10/11/2013. Diabetes- The Real Cost of Sugar. Diabetes 101: What is Diabetes. By Ruth Nekonchuk RD CDE LMNT

Horizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007

1) There is an emerging global epidemic of diabetes that can be traced back to rapid increases in overweight, obesity and physical inactivity

Pre-Dialysis Insulin Information for Patients with Type 2 Diabetes receiving haemodialysis

Diabetes Mellitus Type 2

Number of people with diabetes

Diabetes Mellitus II CPG

Diabetes 101: A Brief Overview of Diabetes and the American Diabetes Association

Victoza (liraglutide) solution for injection 6 mg/ml

Diabetes A to Z Bingo! Donna Tall Bear, MS CHES Certified Health Coach Instructor, Department of Health and Exercise Science

Diabetes and stroke. What is diabetes? What are the symptoms of diabetes? Stroke Helpline: Website: stroke.org.uk

VI.2 Elements for a Public Summary

Diabetes outcomes Keystone 17 July 2014

Fasted and Consented but Blood Glucose 18mmol/L or How to Manage Diabetes in the Peri-Operative Period

Updated August /08/2020

Drug Class Review Monograph GPI Class 27 Anti-diabetics

ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ

Pharmacological Glycaemic Control in Type 2 Diabetes

What s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA

Transcription:

Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh

What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The body s inability to produce insulin (insulin deficiency) And/Or - The body s inability to respond to insulin (insulin resistance)

United Kingdom 6 8% of UK Population is Diabetic Approximately half a million undiagnosed Diabetics in the UK at any one time 5 Million Diabetics in UK by 2025 10% of NHS Budget is spent on Diabetes care (~ 10 Billion)

Type 1 Diabetes Mellitus A disorder of the immune system where the body s own ability to produce insulin is destroyed (nearly 100%) Immune system wrongly target and destroy β-cells in the Pancreas This can only be managed by immediately starting insulin therapy

Type 2 Diabetes Mellitus 95% of all Diabetics are Type 2 Combination of insulin deficiency (though not as much as Type 1 Diabetes Mellitus) and insulin resistance Associated with Obesity, Hypertension and Hypercholesteraemia Managed by a combination of diet, oral medications and injectable therapies (e.g. insulin)

Diabetic Complications Eye Disease Kidney Disease Heart Disease Cerebrovascular Disease Nerve Disease Peripheral Vascular Disease Foot Disease

Some of the potential outcomes of Diabetes! Cataracts Glaucoma Retinopathy Blindness End-Stage Renal Failure Dialysis Kidney Transplant Heart Attack Heart Failure Arrhythmias Mini-Stroke Stroke Sensory Ataxia Painful Peripheral Neuropathy Mononeuritis Multiplex Lumbosacral Plexopathy Muscle Infarction Intermittent Claudication Acute Ischaemia and Necrosis Foot Ulceration Toe Amputation Major Limb Amputation

Diabetic Foot Disease Definition: Localised injury to the skin and/or underlying tissue (below the ankle) in a person with Diabetes 10% of all Diabetics will be diagnosed with a foot ulcer in their lifetime 50% will die within 5 years of developing a diabetic foot ulcer 70% will die within 5 years of having an amputation Diabetes is the most common cause of non-traumatic limb amputation

Risk Factors for Diabetic Foot Disease Neuropathy Peripheral ischaemia Swelling Skin breakdown Infection Deformity Callus

Treatment for Diabetes Type 1 Diabetes Mellitus Multiple daily insulin injections Diet and Exercise Type 2 Diabetes Mellitus Diet, exercise and weight loss Oral and/or injectable anti-diabetic medications (including insulin) Treat Hypertension and Hypercholesteraemia

Aims of Treatment Prevent onset of complications Slow the progression or cause reversal of existing complications Prevent extremes of blood glucose levels (hyperglycaemia, hypoglycaemia) Manage other risk factors e.g. Hypertension, Hypercholesteraemia

NICE Guidance on Type 2 Diabetes Mellitus

Treatment for Diabetes Oral Medication Biguanides Metformin Improve insulin sensitivity Sulphonylureas Gliclazide Enhance insulin secretion Thiazolidinediones Pioglitazone Improve insulin sensitivity DPP4-inhibitors Sitagliptin Enhance effect of beneficial gut hormones GLP-1 Analogues Liraglutide (injection) Synthetic beneficial gut hormone SGLT2 inhibitors Empagliflozin Enhance excretion of glucose into urine

Diabetes and Insulin how far have we come?

Glucose lowering agents types of insulin available Mealtime insulins unmodified human soluble regular rapid-acting analogues Basal insulin NPH insulin protamine complex long-acting analogues Insulin mixes soluble + NPH rapid acting analogues + NPH

Glucose lowering agents possible insulin regimens Type 1 Diabetes Mellitus Fast-acting insulin with meals and 1-2 basal insulin injections optimal Twice daily mix insulin Type 2 Diabetes Mellitus Once Twice daily basal insulin Twice daily mix insulin Fast-acting insulin with meals and 1-2 basal insulin injections

Monitoring Diabetes Daily self-monitoring with use of blood glucose meters Glycosylated Haemoglobin (HbA1c): Spot blood test providing information on average blood glucose over last 2 3 months

Updates in Type 2 Diabetes Mellitus

Personalised Care

New Glucose Lowering Agents GLP-1 Analogues (injection): Synthetic gut hormone which works to reduce weight as well as blood glucose SGLT2 inhibitors: Stimulates the kidney to allow more glucose to be removed in the urine also helping to reduce weight alongside blood glucose

GLP-1 Analogue: Liraglutide injections

SGLT2 Inhibitor: Empagliflozin

SGLT2 Inhibitor: Canagliflozin

Diabetes reversal after <6 months low calorie diet Special formula diet (approximately 820 kcal/day) Nearly 50% had average blood glucose below the diabetic range (in remission ) versus 4% through conventional measures Progressively greater odds of successful remission of Diabetes with a higher amount of weight loss

Updates in Type 1 Diabetes Mellitus

Peptide Vaccine for newly Diagnosed Type 1 Diabetes Mellitus Similar principles to vaccines for infections! Newly diagnosed diabetics given subcutaneous injections every 2 4 weeks for 6 months Preserves insulin production and better diabetic control (and lower insulin doses) in treatment group

Closed-Loop System Artificial Pancreas

Benefits Improved diabetic control (glucose variability and average glucose values Reduced amount of time patients spent with low blood glucose values (hypoglycaemia) Automatic suspension of insulin delivery via pump when blood glucose drops too low

Glucose Monitoring now available on the NHS

Islet Cell Transplantation

Summary Diabetes caused by insulin deficiency and/or resistance Rising numbers UK and worldwide Managed by lifestyle modification, oral and injectable therapies Various developments ongoing!